Skip to main content
Premium Trial:

Request an Annual Quote

Biotechs Pooh-Pooh Brute Force to Woo Investors with Rational Drug Discovery


Technology-driven biotech companies looking to court the financial community at this year’s BIO-CEO Investor conference in New York were singing a slightly modified tune from that of previous years. While the recent trend at such meetings has been to de-emphasize genomics-driven approaches — especially those that rely on platform-related business models — speakers at this year’s conference distanced themselves from high-throughput technology altogethe: from genomics and proteomics to combinatorial chemistry, high-throughput screening, and even high-performance computing.

The new mantra, apparently, is an approach that foregoes brute force and serendipity in favor of predictive methods that rely on hypothesis-driven experiments. Compugen chairman Martin Gerstel said that the probability of success with high-throughput tools is as slim as buying a lottery ticket, and that the propagation of such methods across the industry is comparable to “buying even more tickets to more lotteries.”

Compugen, along with several other companies presenting at the conference, touted a “rational” approach that places the goal of a better understanding of biological systems over brute-force data-gathering methods. This approach, while smaller in scale than the industrial biology-style methodology of the genomic era, still presents an opportunity for computational tools — even if high-powered number-crunching machines are left out of the picture. Michael French, senior vice president of Entelos, pointed out that although systems-scale computational methods are complex, they still don’t need the IT power required for sequencing the human genome. “The new methodology is in the software,” he said. In response to a question as to why drug discovery companies don’t partner with large IT firms for biological modeling, French said that the methods that Entelos and others use “don’t require a Cray to crunch a number.” Because the approach relies on solving “lots of smaller problems quickly,” distributed systems based on commodity hardware work just fine, he said.

Other companies, such as Array Biopharma, Curagen, and Cyclacel, said they are relying on simulation and predictive modeling to place the vast amounts of data gathered through high-throughput approaches into the proper biological context. Kevin Koch, president and CSO of Array Biopharma, said that companies who invested heavily in genomics or combinatorial chemistry with little payoff in terms of new drug candidates “forgot something critical” in the process. The key issue in biopharma over the next decade, he said, will be “to interpret and make good decisions” based on the wealth of data that is already available.

— BT


Filed under

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.